BGI

BGI Group and its spin-off MGI manufacture high-throughput DNBSeq sequencers—including BGISEQ‑500, MGISEQ‑2000, and DNBSeq‑G series—as cost-effective alternatives to Illumina’s NGS platforms.

BGI launched the BGISEQ‑500 in 2015, and by late 2016 had deployed over 150 units in China’s National Genebank .
MGI (listed in Shanghai since 2022) continues advancing DNBSeq technology and lab automation, serving both research and healthcare sectors.